| Breast Cancer Subtype | Enriched (P≤0.01) | Depleted (P≤0.01) |
|-----------------------|-------------------|-------------------|
|                       | Protective | Hazardous | Pro+Haz | Protective | Hazardous | Pro+Haz |
| **Histological Subtypes** |          |          |         |          |          |         |
| Triple-positive        | 46 (30)   | 43 (27)  | 40 (26) | 143 (98) | 0 (0)     | 72 (54) |
| Triple-negative        | 41 (26)   | 0 (0)    | 14 (11) | 12 (11)   | 0 (0)     | 1 (1)   |
| PR+                   | 69 (53)   | 32 (25)  | 37 (30) | 135 (92)  | 0 (0)     | 106 (78) |
| PR-                   | 116 (76)  | 30 (19)  | 128 (83)| 129 (95)  | 0 (0)     | 135 (98) |
| HER+                  | 36 (26)   | 106 (62) | 67 (47) | 54 (41)   | 15 (14)   | 61 (46) |
| HER-                  | 91 (62)   | 32 (22)  | 89 (59) | 117 (85)  | 2 (2)     | 76 (59) |
| ER+                   | 102 (77)  | 99 (62)  | 80 (60) | 161 (113) | 7 (6)     | 150 (103)|
| ER-                   | 69 (49)   | 14 (11)  | 10 (8)  | 21 (19)   | 28 (22)   | 14 (13) |
| **Intrinsic Subtypes** |          |          |         |          |          |         |
| Basal                 | 0 (0)     | 26 (16)  | 6 (4)   | 1 (1)     | 2 (2)     | 0 (0)   |
| HER2-enriched         | 0 (0)     | 0 (0)    | 0 (0)   | 0 (0)     | 0 (0)     | 0 (0)   |
| Luminal A             | 9 (6)     | 119 (72) | 102 (61)| 13 (11)   | 29 (25)   | 40 (34) |
| Luminal B             | 0 (0)     | 64 (42)  | 5 (4)   | 7 (5)     | 0 (0)     | 0 (0)   |